<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Immune checkpoint inhibitor colitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Immune checkpoint inhibitor colitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Immune checkpoint inhibitor colitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Yinghong Wang, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Dougan, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3028288436"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>With the widespread use of immune checkpoint inhibitors (ICI; also known as checkpoint inhibitor immunotherapy) for treatment of various types of cancer, immune-related adverse events (irAEs) are becoming increasingly common. </p><p>This topic will review the clinical presentation, diagnosis, and management of ICI colitis. Hepatic, pancreatic, and rare gastrointestinal toxicities of ICI, as well as those involving other organ systems, are presented separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/134862.html" rel="external">"Hepatic, pancreatic, and rare gastrointestinal complications of immune checkpoint inhibitor therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors"</a>.)</p><p></p><p class="headingAnchor" id="H626893934"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>ICI diarrhea and colitis are defined by the American Society of Clinical Oncology (ASCO) based on symptoms alone rather than by colonic inflammation that is demonstrated by endoscopic findings (mucosal inflammation with or without ulcers  (<a class="graphic graphic_table graphicRef65649 graphicRef138439" href="/d/graphic/65649.html" rel="external">table 1A-B</a>)) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Diarrhea is defined as watery bowel movements with any increase in stool frequency over baseline.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colitis involves abdominal pain, mucus or blood in the stools, and fever.</p><p></p><p>Although the Common Terminology Criteria for Adverse Events (CTCAE, also called "common toxicity criteria") categorizes ICI diarrhea and ICI colitis separately, these conditions (and their management) overlap and they likely represent a spectrum of histopathologic disease [<a href="#rid2">2</a>]. In addition, the terms ICI diarrhea and ICI colitis are often used interchangeably, and the condition has also been referred to as ICI enterocolitis, immune-mediated colitis (IMC), or immune-mediated diarrhea and colitis (IMDC).</p><p>For patients who are on ICI therapy alone, clinical variability exists for the grading of these toxicities. At some institutions, each toxicity is graded and reported separately (ie, one grade for diarrhea symptoms and another for colitis symptoms), while other institutions only report the toxicity with the higher grade.</p><p>Of note, ICIs can be combined with either chemotherapy or targeted agents to treat certain cancers. The assessment of diarrhea or colitis symptoms in patients receiving such combination therapy may be different from those receiving ICIs alone, since the diarrhea may be related to the additional systemic agent. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation"</a> and  <a class="medical medical_review" href="/d/html/98342.html" rel="external">"Management of acute chemotherapy-related diarrhea"</a>.)</p><p class="headingAnchor" id="H2977784999"><span class="h1">INCIDENCE AND RISK FACTORS</span><span class="headingEndMark"> — </span>ICI colitis is the most frequently reported gastrointestinal immune-related adverse event (irAE). The reported overall incidence of ICI colitis ranges between 1 and 25 percent and varies based on the specific agent, dose, and combination of ICIs used [<a href="#rid3">3</a>]. As an example, cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors or combination regimens (eg, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>) are associated with increased risk of developing ICI colitis and of progressing to severe colitis compared with single-agent programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors [<a href="#rid4">4-6</a>]. In addition, studies have suggested that higher doses of CTLA-4 therapy are associated with a greater risk of developing colitis [<a href="#rid7">7-9</a>].</p><p>Other factors that have been associated with the risk and severity of ICI colitis include the type of malignancy [<a href="#rid10">10</a>], composition of the intestinal microbiome [<a href="#rid11">11</a>], and lack of vitamin D supplementation [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H563762344"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>T cells are critical to the efficacy of ICI therapy. The immune checkpoints cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) both attenuate T cell activation though distinct mechanisms. PD-1 sends a direct inhibitory signal through activation of phosphatases after binding to its ligands programmed cell death ligand 1 (PD-L1) or programmed cell death ligand 2 (PD-L2), and CTLA-4 binds the costimulatory ligands CD80 and CD86, preventing them from interacting with the T cell costimulatory receptor CD28. Additionally, CTLA-4 is constitutively expressed on regulatory T cells (Tregs) and is essential for many of their immune suppressive functions [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a>.)</p><p>Complications from ICI therapy arise from blockade of these important regulatory pathways. Although any organ system can be affected by ICI-related toxicities, these toxicities most often affect the skin, gastrointestinal tract, liver, and the respiratory epithelium [<a href="#rid13">13</a>]. Expanded CD8+ T cells and, to a lesser extent, CD4+ T cells have been found in histopathologic analyses from multiple organs affected by ICI toxicity, and this is consistent with findings in tumors [<a href="#rid14">14-16</a>]. In ICI colitis, CD8+ T cells are likely expanded from the mucosal resident memory cells [<a href="#rid17">17,18</a>]. These expanded cells express markers of proliferation and cytotoxicity and produce the cytokine interferon (IFN)-gamma [<a href="#rid17">17,18</a>]. In addition, ICI colitis is associated with an expansion of IFN-gamma producing Th1 CD4+ T cells, further implicating this cytokine in disease pathogenesis [<a href="#rid17">17,18</a>]. IFN-gamma overexpression is not unique to colitis from ICI as it appears to be critical for antitumor responses as well [<a href="#rid19">19,20</a>]. Tregs are expanded in ICI colitis, though they likely have decreased function, particularly in the setting of CTLA-4 inhibitors [<a href="#rid17">17,18</a>]. </p><p>The targets of the T cell response in the gastrointestinal tract are not known, but the diversity of T cells identified is consistent with recognition of the microbiome [<a href="#rid18">18</a>]. Alterations in the microbiome have been observed in patients who are susceptible to colitis from ICI therapy, and modulation of the gut microbiome is the basis for studies that use fecal microbiota transplant (FMT) for patients with ICI colitis who do not respond to initial therapy [<a href="#rid21">21,22</a>]. (See <a class="local">'Nonresponders to initial biologic agent'</a> below.)</p><p>In addition to the expansion of resident memory cells, ICI colitis is associated with an inflammatory macrophage population that is responding to and producing tumor necrosis factor (TNF)-alpha and producing the chemokines CXCL9 and CXCL10, both of which likely recruit additional T cells from the blood into the colon, further exacerbating colitis [<a href="#rid18">18</a>]. The importance of these findings is underscored by the response to anti-TNF agents, as well as to inhibitors of T cell trafficking such as <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a>.</p><p>Precisely how each of these factors contributes to epithelial cell damage in ICI colitis is uncertain. However, both TNF-alpha and IFN-gamma may cause cell dysfunction and increased susceptibility to apoptosis. Effector CD8+ T cells may also be causing direct cytotoxicity.</p><p class="headingAnchor" id="H1220008326"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H1053588884"><span class="h2">Patient presentation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of symptom onset</strong> — For most patients with ICI colitis, symptoms develop within a few weeks to a few months after starting ICI therapy [<a href="#rid4">4,5,23</a>]. Although colitis can present at any time during the course of ICI therapy, it rarely develops extremely early (ie, within the first few days) or extremely late (ie, years) after the initiation of therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> — Patients with ICI colitis usually present with diarrhea (ie, loose stools with an increase in stool frequency over baseline  (<a class="graphic graphic_table graphicRef65649 graphicRef138439" href="/d/graphic/65649.html" rel="external">table 1A-B</a>)), although the frequency of diarrhea can vary clinically. In those with more severe disease, diarrhea may be associated with cramping abdominal pain, urgency, and rectal bleeding. Some patients report symptoms such as nausea, vomiting, and early satiety that suggest upper gastrointestinal tract involvement (ie, gastritis and/or enteritis).</p><p></p><p class="bulletIndent1">Less typical symptoms include fever, abdominal distension, and/or severe abdominal pain. These symptoms should raise suspicion for severe disease and/or a possible complication such as colonic perforation or toxic megacolon. (See  <a class="medical medical_review" href="/d/html/15075.html" rel="external">"Overview of gastrointestinal tract perforation"</a> and  <a class="medical medical_review" href="/d/html/1381.html" rel="external">"Toxic megacolon"</a>.)</p><p></p><p>Studies on ICI colitis use an oncology-based grading system called the Common Terminology Criteria for Adverse Events (CTCAE), which relies solely on symptoms and classifies toxicities on a scale from grade 1 (mild) to grade 5 (death  (<a class="graphic graphic_table graphicRef65649 graphicRef138439" href="/d/graphic/65649.html" rel="external">table 1A-B</a>)) [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3001674605"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Physical examination may be normal in patients with mild disease, whereas patients with moderate to severe disease may have abdominal tenderness with or without abdominal distension. The presence of guarding, rigidity, or rebound tenderness on examination suggests the presence of a complication such as colonic perforation or toxic megacolon. (See  <a class="medical medical_review" href="/d/html/6862.html" rel="external">"Evaluation of the adult with abdominal pain"</a>.)</p><p class="headingAnchor" id="H1920749444"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Routine laboratory tests may be normal, or they may reveal an elevated white blood cell count, an elevated C-reactive protein, or electrolyte abnormalities. Stool inflammatory markers (fecal calprotectin or lactoferrin) may be elevated due to intestinal inflammation [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H4238028304"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>The diagnosis of ICI colitis should be suspected in patients who are receiving ICI therapy and who develop diarrhea with or without bleeding or abdominal pain.</p><p>Goals of the diagnostic evaluation for patients with suspected ICI colitis are to exclude other causes of colitis and establish the diagnosis. The evaluation should occur promptly (ie, within a few days after symptoms are reported) because colitis may progress quickly without treatment.</p><p>The diagnosis of ICI colitis is established clinically by assessing symptoms according to CTCAE and excluding other causes (eg, infection). The diagnosis may be further confirmed with endoscopic evaluation with biopsy [<a href="#rid2">2</a>]. </p><p class="headingAnchor" id="H861873749"><span class="h2">Approach to testing</span><span class="headingEndMark"> — </span>The approach to diagnostic testing is informed by severity of symptoms and suspicion for disease progression:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory studies</strong> – For all patients in whom ICI colitis is suspected, laboratory studies including blood tests and stool studies are obtained. (See <a class="local">'Laboratory studies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endoscopic evaluation</strong> – For patients with grade 2 to 4 symptoms and/or an elevated stool inflammatory marker, we typically perform a lower endoscopy (eg, flexible sigmoidoscopy) with biopsies  (<a class="graphic graphic_table graphicRef65649 graphicRef138439" href="/d/graphic/65649.html" rel="external">table 1A-B</a>). While flexible sigmoidoscopy is the initial test of choice, some contributors start with an ileocolonoscopy to also assess for right-sided colitis or ileitis. For patients with a normal flexible sigmoidoscopy or colonoscopy and persistent symptoms, subsequent testing includes upper esophagogastroduodenoscopy (EGD). (See <a class="local">'Endoscopic evaluation'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging studies</strong> – For patients with a suspected complication (eg, those with fever, severe abdominal pain, abdominal distension, and/or rectal bleeding), we perform cross-sectional imaging (computed tomography [CT] of the abdomen and pelvis) prior to endoscopic evaluation to exclude complications of ICI colitis (eg, bowel perforation or toxic megacolon) as well as potential cancer progression. (See <a class="local">'Imaging studies'</a> below.)</p><p></p><p class="headingAnchor" id="H2119791512"><span class="h2">Laboratory studies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood tests </strong>–We obtain complete blood count, complete metabolic panel (CMP), thyroid stimulating hormone (TSH), tissue transglutaminase (TTG) IgA-antibody, total IgA level, and a serum inflammatory marker (eg, C-reactive protein [CRP]). While CRP as a serologic marker of inflammation has largely replaced the erythrocyte sedimentation rate (ESR), some clinicians may only have access to ESR. </p><p></p><p class="bulletIndent1">For patients with fever, we also obtain blood cultures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stool studies</strong> – Stool studies include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Testing for enteric pathogens</strong> – We typically obtain stool testing for infection (ie, <em>Clostridioides difficile </em>[<a href="#rid25">25</a>], routine stool cultures [Salmonella, Shigella, Campylobacter, Yersinia], and specific testing for E. coli O157:H7). For patients with risk factors for parasitic infection (eg, recent travel to a region where parasitic infections are endemic), stool microscopy for ova and parasites (three specimens) and a Giardia stool antigen test are also checked. We do not routinely assess for intestinal amebiasis (<em>E. histolytica</em>). Stool analysis for the detection of pathogens is discussed in more detail separately:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/d/html/8305.html" rel="external">"Approach to the diagnosis of cytomegalovirus infection", section on 'Gastrointestinal disease'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/d/html/5723.html" rel="external">"Giardiasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stool inflammatory markers</strong> – We typically check a stool inflammatory marker (lactoferrin or calprotectin) at initial diagnosis. Elevated stool inflammatory markers can help to confirm a diagnosis of ICI colitis if other causes have also been ruled out. Nevertheless, in patients with elevated markers (regardless of disease severity), lower endoscopy is still necessary to assess for infectious causes of colitis, grade the severity of mucosal inflammation, and clarify the diagnosis if there are conflicting or borderline stool marker results. For patients with grade 1 or 2 symptoms where lower endoscopy is delayed, stool markers can also be used to noninvasively assess for colonic inflammation. (See <a class="local">'Endoscopic evaluation'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Elevated stool markers</strong> – Calprotectin is borderline elevated if levels are between 50 and 120 mcg/g and elevated if greater than 120 mcg/g [<a href="#rid26">26</a>]. Lactoferrin is elevated when positive for inflammation, although some laboratories provide quantitative results. If the stool marker is elevated (in particular, lactoferrin due to its high sensitivity), colonic inflammation is likely to be found on lower endoscopy. In one study including 182 patients with suspected ICI colitis, the sensitivity for elevated fecal lactoferrin to predict endoscopic or histologic inflammation was 70 and 90 percent, respectively [<a href="#rid24">24</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Normal stool markers</strong> – For patients whose stool markers are normal (calprotectin levels &lt;50 mcg/g or negative lactoferrin), we typically defer lower endoscopy (especially if symptoms have completely resolved). However, the absence of elevated stool inflammatory markers does not exclude the possibility of diarrhea due to ICI colitis or ICI enteritis. [<a href="#rid27">27</a>]. </p><p></p><p class="bulletIndent2">Stool inflammatory markers can also be used for subsequent monitoring of treatment response. (See <a class="local">'Monitoring patients with symptomatic remission'</a> below.)</p><p></p><p class="headingAnchor" id="H1372732176"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>In patients who are suspected to have a complication (eg, fever, severe abdominal pain, abdominal distension, and/or rectal bleeding), we perform cross-sectional imaging (CT scan of the abdomen and pelvis). In such patients, abdominal CT can exclude complications of ICI colitis as well as disease progression [<a href="#rid28">28</a>]. (See <a class="local">'Complications'</a> below.) </p><p>Patients on ICI therapy may be incidentally diagnosed with colitis on routine CT imaging obtained during cancer restaging. Such patients should also be appropriately evaluated for potential etiologies of the colitis, including ICI colitis. (See <a class="local">'Differential diagnosis'</a> below and <a class="local">'Diagnostic evaluation'</a> above.)</p><p>When imaging features of ICI colitis are present, they typically include colonic inflammation demonstrated by wall thickening and mucosal hyperenhancement in a diffuse or segmental distribution [<a href="#rid28">28</a>]. However, for most patients, CT does not demonstrate specific features of ICI colitis, and studies have shown poor correlation between imaging and endoscopic findings [<a href="#rid27">27,29</a>]. </p><p class="headingAnchor" id="H522368273"><span class="h2">Endoscopic evaluation</span><span class="headingEndMark"> — </span>For patients with grade 2 to 4 symptoms  (<a class="graphic graphic_table graphicRef65649 graphicRef138439" href="/d/graphic/65649.html" rel="external">table 1A-B</a>), we typically perform a lower endoscopy (eg, flexible sigmoidoscopy) to evaluate for mucosal disease and obtain biopsies to exclude infection (eg, cytomegalovirus). (See  <a class="medical medical_review" href="/d/html/8305.html" rel="external">"Approach to the diagnosis of cytomegalovirus infection", section on 'Gastrointestinal disease'</a>.)</p><p>Because most patients have left colon involvement, a flexible sigmoidoscopy is the initial test of choice rather than ileocolonoscopy because the diagnosis can be established while minimizing the risk of colonic dilation and perforation [<a href="#rid30">30,31</a>]. Alternatively, some contributors start with an ileocolonoscopy, as the incidence of isolated right-sided colitis or ileitis is approximately 10 percent. Patients with persistent diarrhea and a normal flexible sigmoidoscopy or colonoscopy should be evaluated with EGD. </p><p>Endoscopic features of ICI colitis are usually nonspecific and range from a normal endoscopic appearance to mucosal inflammation with or without ulceration  (<a class="graphic graphic_picture graphicRef96623" href="/d/graphic/96623.html" rel="external">picture 1</a>).</p><p>Although there is no consensus for the approach to grading the endoscopic severity of ICI colitis, the Mayo Clinic ulcerative colitis (UC) endoscopic scoring system is frequently used in clinical practice (<a class="calc calc_professional" href="/d/html/15644.html" rel="external">calculator 1</a>) [<a href="#rid32">32</a>]. In addition, the following endoscopic features are associated with increased risk for disease that does not respond to glucocorticoids [<a href="#rid33">33</a>], overall worse outcomes, and the need for second-line therapy to achieve clinical improvement [<a href="#rid24">24,27</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Large ulcers &gt;1 cm</p><p class="bulletIndent1"><span class="glyph">●</span>Deep ulcers &gt;2 mm</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple ulcers (3 or more)</p><p class="bulletIndent1"><span class="glyph">●</span>Extensive colitis (ie, mucosal involvement proximal to the left colon)</p><p></p><p>During lower endoscopy, biopsies are routinely obtained from the left colon and rectum even if endoscopically normal in appearance to assess for histologic evidence of inflammation. Histologic findings in most patients with acute ICI colitis include neutrophil and/or eosinophil infiltration, epithelial apoptosis, cryptitis, and crypt abscesses. Some patients have histologic features of chronic colitis such as crypt architectural distortion, basal lympho-plasmocytosis, granulomas, and Paneth cell metaplasia [<a href="#rid24">24,27</a>]. </p><p>Some patients with ICI colitis have minimal mucosal inflammation without ulceration but have more predominant histologic inflammation [<a href="#rid34">34-36</a>]. In addition, some patients lack both endoscopic and histologic inflammation on initial endoscopic evaluation [<a href="#rid24">24</a>]. Such patients may have either enteritis (inflammation of the small intestine) which can be confirmed with EGD and duodenal biopsies or with ileocolonoscopy and ileal biopsies; an alternative cause of diarrhea; or an uncommon condition known as "noncolitis ICI-related diarrhea" that is characterized by ICI-related diarrhea without colitis [<a href="#rid27">27</a>].</p><p>There is also a subset of patients with ICI colitis who have histologic features of microscopic colitis (lymphocytic infiltration) with or without visible mucosal inflammation [<a href="#rid35">35,36</a>], and such patients are discussed below. (See <a class="local">'ICI-mediated microscopic colitis'</a> below.)</p><p class="headingAnchor" id="H1471485145"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for acute ICI colitis is broad and includes etiologies that share a similar clinical presentation and overlapping symptoms (diarrhea, abdominal pain).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious colitis or enterocolitis</strong> – Patients with infectious colitis or enterocolitis (small bowel inflammation) typically report the acute onset of diarrhea, and stool studies are performed to evaluate for enteric pathogens (eg, <em>Clostridioides difficile</em>, <em>Salmonella</em>). (See  <a class="medical medical_review" href="/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings"</a>.)</p><p></p><p class="bulletIndent1">In immunocompromised patients, cytomegalovirus (CMV) infection can mimic ICI colitis or enterocolitis. This can also be an important cause of recurrent/refractory colitis in patients undergoing ICI colitis treatment. (See  <a class="medical medical_review" href="/d/html/8289.html" rel="external">"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Gastrointestinal manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ICI-related enteritis</strong> – ICI-related enteritis (involving the small bowel) can also present with symptoms that mimic ICI colitis. ICI enteritis can be evaluated endoscopically with esophagogastroduodenoscopy (EGD) and/or ileocolonoscopy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperthyroidism</strong> – Patients with hyperthyroidism and/or an endocrinologic immune-related adverse event (irAE) may present with gastrointestinal symptoms that are similar to ICI colitis (loose stools). We routinely screen for thyroid dysfunction by checking thyroid stimulating hormone (TSH) as part of the initial evaluation for suspected ICI colitis. (See  <a class="medical medical_review" href="/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism"</a> and  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Endocrinopathies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ischemic colitis</strong> – The clinical presentation of ischemic colitis may overlap with ICI colitis and includes lower abdominal pain and bloody diarrhea or hematochezia. The pattern of mucosal involvement on CT scan of the abdomen, endoscopic appearance of the mucosa on lower endoscopy (edematous, friable mucosa; erythema; and interspersed pale areas), and histologic evidence of ischemic colitis can establish the diagnosis of ischemic colitis. (See  <a class="medical medical_review" href="/d/html/2564.html" rel="external">"Colonic ischemia", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Celiac disease</strong> – Celiac disease is a small bowel disorder characterized by mucosal inflammation and villous atrophy which occur in response to dietary gluten. Patients with celiac disease may present with gastrointestinal symptoms that are similar to ICI colitis (eg, diarrhea, abdominal pain). Serologic evaluation (ie, tissue transglutaminase-IgA antibody) is typically performed to detect celiac disease in adults. The clinical manifestations and diagnosis of celiac disease are presented separately. (See  <a class="medical medical_review" href="/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"</a> and  <a class="medical medical_review" href="/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults"</a>.)</p><p></p><p class="bulletIndent1">Celiac disease may manifest either as a de novo diagnosis unrelated to ICI therapy or as a rare manifestation of immunotherapy-related toxicity. (See  <a class="medical medical_review" href="/d/html/134862.html" rel="external">"Hepatic, pancreatic, and rare gastrointestinal complications of immune checkpoint inhibitor therapy", section on 'Rare GI toxicities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy involving the GI tract</strong> – Some gastrointestinal (GI) malignancies present with diarrhea and/or rectal bleeding. Examples include intestinal involvement from the primary cancer or metastatic disease (eg melanoma metastases to the GI tract) [<a href="#rid37">37</a>], or a separate primary cancer that could affect the colon (eg, colorectal cancer, neuroendocrine tumors, gynecologic malignancies). (See  <a class="medical medical_review" href="/d/html/7625.html" rel="external">"Imaging studies in melanoma", section on 'Gastrointestinal tract'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pancreatic insufficiency</strong> – Patients with pancreatic insufficiency may report chronic diarrhea with pale, greasy, voluminous, foul-smelling stools and unintentional weight loss despite adequate food intake. Abdominal pain is unusual. We screen for maldigestion due to pancreatic insufficiency with fecal elastase. (See  <a class="medical medical_review" href="/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irritable bowel syndrome</strong> – Patients with undiagnosed irritable bowel syndrome (IBS) may have the condition triggered by the stress of cancer treatment. Such patients may be incidentally diagnosed with this condition during the assessment for ICI colitis. (See  <a class="medical medical_review" href="/d/html/2630.html" rel="external">"Clinical manifestations and diagnosis of irritable bowel syndrome in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diarrhea due to chemotherapy or antiangiogenic agents administered with ICI </strong>– Patients who are treated with a combination of ICI and chemotherapy may present with diarrhea that is specifically related to chemotherapy alone. Chemotherapy-related diarrhea often presents with a waxing and waning pattern of increased bowel movements and/or loose stools that correlates with treatment cycles. This pattern can help to distinguish it from ICI diarrhea or ICI colitis, which typically present with persistent diarrhea that occurs independently of administering or holding subsequent ICI cycles. For patients who undergo endoscopic evaluation and biopsy, chemotherapy-related diarrhea demonstrates a pattern of toxic injury with minimal inflammation on histology. (See  <a class="medical medical_review" href="/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation"</a> and  <a class="medical medical_review" href="/d/html/98342.html" rel="external">"Management of acute chemotherapy-related diarrhea"</a>.)</p><p></p><p class="bulletIndent1">Immunotherapy can also be administered in combination with targeted therapy (eg, antiangiogenic therapy in patients with advanced or renal cell carcinoma). Symptoms of diarrhea or colitis in patients on this combination therapy is more commonly due to the antiangiogenic agent rather than the immunotherapy. (See  <a class="medical medical_review" href="/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Risk with molecularly targeted agents'</a>.)</p><p></p><p class="bulletIndent1">For patients on combination therapy with symptoms of diarrhea, our initial approach is to hold the antiangiogenic agent and provide supportive care. In patients whose symptoms do not improve after holding antiangiogenic therapy, diarrhea due to ICI colitis should be suspected. For such patients who are being evaluated for possible immunosuppressive therapy, we obtain endoscopic evaluation with biopsies. Diarrhea due to targeted agents typically reveals a lack of toxic mucosal injury on endoscopic evaluation; however, biopsies are still necessary because the absence of mucosal injury does not exclude the possibility of ICI colitis.</p><p></p><p class="headingAnchor" id="H2525665482"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3739264243"><span class="h2">Goals</span><span class="headingEndMark"> — </span>The goals of treatment for patients with ICI colitis are resolution of symptoms, avoiding complications, and either continuing or reintroducing ICI therapy when possible. (See <a class="local">'Resuming immune checkpoint inhibitors'</a> below.)</p><p>Our approach to therapy for ICI colitis is informed by the Common Terminology Criteria for Adverse Events (CTCAE) grade severity, which is consistent with guidelines from the American Society of Clinical Oncology (ASCO) [<a href="#rid38">38</a>]. For patients with different grading for diarrhea and colitis, we use the higher grade to guide treatment decisions.</p><p class="headingAnchor" id="H2711210244"><span class="h2">Mild disease (grade 1)</span><span class="headingEndMark"> — </span>We treat patients with grade 1 symptoms (ie, increase of ≤3 watery stools daily over baseline and no abdominal pain  (<a class="graphic graphic_table graphicRef65649 graphicRef138439" href="/d/graphic/65649.html" rel="external">table 1A-B</a>)) with supportive care while continuing ICI therapy because grade 1 symptoms are generally mild and self-limiting. We do not initiate systemic glucocorticoids in these patients.</p><p>Supportive care includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diet </strong>– We advise patients to maintain adequate oral hydration and adhere to a bland, lactose-free diet with no/reduced caffeine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic therapy</strong> – For patients with stool studies that are negative for infection, antidiarrheal agents can be used as needed as a temporary measure in patients with diarrhea only and no colitis-related symptoms. We typically use <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a> 2 to 4 mg every four hours as needed, not to exceed 16 mg in 24 hours.</p><p></p><p class="bulletIndent1">However, some contributors avoid the use of antidiarrheal agents for all patients due to the risk of toxic megacolon. In this situation, alternatives to <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a> include <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> 4 grams twice daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ICI therapy</strong> – ICI therapy is typically continued. However, holding ICI therapy and resuming it after symptoms resolve may be a reasonable option that is individualized and informed by oncologist preference and indication for ICI therapy.</p><p></p><p>Patients with grade 1 symptoms who do not respond to supportive care are managed similarly to those with grade ≥2 symptoms. (See <a class="local">'Moderate to severe disease (grade 2 to 4)'</a> below.)</p><p class="headingAnchor" id="H2370406156"><span class="h2">Moderate to severe disease (grade 2 to 4)</span></p><p class="headingAnchor" id="H3295162100"><span class="h3">Initial management</span><span class="headingEndMark"> — </span>For patients with moderate to severe disease (grade 2 to 4 symptoms  (<a class="graphic graphic_table graphicRef65649 graphicRef138439" href="/d/graphic/65649.html" rel="external">table 1A-B</a>)), it is important to initiate therapy promptly, as symptoms and disease severity can escalate rapidly without treatment. Initial measures include  (<a class="graphic graphic_algorithm graphicRef138880" href="/d/graphic/138880.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discontinue ICI therapy</strong> – We hold ICI therapy temporarily for grades 2 and 3 symptoms and typically discontinue it permanently for grade 4 symptoms [<a href="#rid38">38-40</a>]. ICI antibodies are still likely to exert substantial biologic activity for weeks to months after stopping treatment, unless immunosuppressive therapy is administered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obtain gastroenterology consultation</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiate systemic glucocorticoid therapy</strong> – We confirm that gastrointestinal infection has been excluded based on stool studies prior to initiating systemic glucocorticoid therapy. (See <a class="local">'Laboratory studies'</a> above.)</p><p></p><p class="bulletIndent1">The route of administration for glucocorticoid therapy is informed by the disease severity and need for inpatient hospitalization:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with grade 2 or 3 diarrhea but without systemic symptoms (eg, fever, hypotension) and who are tolerating oral intake (ie, fluids and bland diet), we suggest initiating oral glucocorticoid therapy. We begin oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> at 1 mg/kg/day (with no specific maximum dose) or an equivalent agent. When symptoms improve to grade 1 diarrhea (&lt;4 loose stools daily over baseline), we gradually taper prednisone by 10 mg every five to seven days with the goal of discontinuing prednisone over four to six weeks  (<a class="graphic graphic_table graphicRef135048" href="/d/graphic/135048.html" rel="external">table 2</a>). Glucocorticoids should not be used long-term due to significant side effects. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="bulletIndent2">Patients who do not have clinical improvement with oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> in three days are escalated to intravenous glucocorticoid therapy or biologic therapy. Hospitalization of these patients is often necessary for prompt treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with grade 4 symptoms and patients with grade 2 or 3 symptoms who have systemic symptoms (eg, fever, hypotension) and/or are not tolerating oral intake require inpatient hospitalization. For such patients, we give <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 1 to 2 mg/kg daily intravenously in two divided doses every 12 hours with a maximum total daily dose of 120 mg.</p><p></p><p class="bulletIndent2">Most patients who respond to intravenous glucocorticoids will have symptomatic improvement (ie, fewer stools, less abdominal pain) with a goal of achieving grade 1 symptoms within three days after starting therapy. For patients who have no clinical improvement within three days of starting systemic glucocorticoids, we initiate second-line therapy with either <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a>. (See <a class="local">'Subsequent management (biologic agents)'</a> below.)</p><p></p><p class="bulletIndent1">For patients who respond (ie, improvement to grade 1 symptoms), we discontinue intravenous glucocorticoids and begin an equivalent dose using an oral formulation such as <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> prior to hospital discharge.</p><p></p><p class="bulletIndent1">Hospitalized patients are reassessed daily to determine if they are eligible to be discharged. Patients must meet all criteria listed below before they can be discharged from the hospital:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normalization of vital signs (ie, resolution of fever, hypotension)</p><p class="bulletIndent2"><span class="glyph">•</span>&lt;4 stools per day over baseline (grade 1 symptoms)</p><p class="bulletIndent2"><span class="glyph">•</span>Resolution of severe abdominal pain</p><p class="bulletIndent2"><span class="glyph">•</span>Tolerance of oral diet</p><p></p><p>The use of systemic glucocorticoids is based on retrospective series [<a href="#rid10">10,41-43</a>], clinical experience, and expert opinion [<a href="#rid38">38</a>]. Randomized trials evaluating glucocorticoid therapy for patients with ICI colitis are lacking.</p><p class="headingAnchor" id="H2813360571"><span class="h3">Subsequent management (biologic agents)</span><span class="headingEndMark"> — </span>For patients who do not have symptomatic response within three days of receiving intravenous glucocorticoid therapy or those with high-risk endoscopic features (eg, colonic ulcers with Mayo Endoscopic score 3 or greater (<a class="calc calc_professional" href="/d/html/15644.html" rel="external">calculator 1</a>)), we suggest the addition of a biologic agent (either <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a>) to glucocorticoid therapy rather than glucocorticoids alone or other agents. In hospitalized patients with glucocorticoid refractory ICI colitis, data suggest that efficacy is comparable between these two agents [<a href="#rid44">44</a>]. Therefore, the selection of infliximab versus vedolizumab is based on clinician preference, patient comorbidities, the type of cancer, and the need for rapid treatment response.</p><p>We obtain pretreatment screening <strong>prior to</strong> initiating biologic agents, and this is discussed separately. (See  <a class="medical medical_review" href="/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults", section on 'Pretreatment screening'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infliximab</strong> – For most patients, we initiate <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> at an initial dose of 5 mg/kg intravenously, at zero, two, and six weeks. Patients with grade 4 colitis and severe hypoalbuminemia (serum albumin &lt;2.5 g/dL) may be treated with an initial dose of 10 mg/kg. While most UpToDate contributors administer three induction doses of infliximab, others do not administer all three doses unless there are persistent symptoms.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> is preferred for patients who require a rapid treatment response and those with concurrent inflammatory arthritis. Patients can demonstrate a partial clinical response (ie, fewer stools, tolerating oral intake) to infliximab as early as 72 hours and generally within less than one week.</p><p></p><p class="bulletIndent1">Pretreatment screening, dosing, monitoring, and adverse effects associated with anti-tumor necrosis factor (TNF) agents are discussed separately:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults", section on 'Tumor necrosis factor inhibitors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p></p><p class="bulletIndent1">Contraindications to the use of anti-TNF therapies (briefly summarized) include the following (see  <a class="medical medical_review" href="/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Use of TNF inhibitors'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active uncontrolled infection</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Latent (untreated) tuberculosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Demyelinating disease (eg, multiple sclerosis, optic neuritis)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Heart failure</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although anti-TNF therapies may be associated with a risk of cancer, we do not avoid <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> in patients with hematologic malignancies if it is indicated for the treatment of ICI colitis and if administered over a limited period of time. (See  <a class="medical medical_review" href="/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vedolizumab</strong> – We typically use standard induction dosing of <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> (300 mg, intravenously, at zero, two, and six weeks). While most UpToDate contributors administer three doses of vedolizumab, others do not administer all three doses unless there are persistent symptoms. Patients typically demonstrate a clinical response (ie, fewer stools, tolerating oral intake) within one to two weeks. Vedolizumab is preferred in patients with hematologic malignancies or for those with an ongoing tumor response to ICI therapy where the impact of systemic immunosuppression needs to be minimized. It can also be used in those who are able to tolerate a slightly slower treatment response, since the clinical response for vedolizumab is less rapid than that seen for <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>. However, it is important to note that patients with ICI colitis respond faster than those with other forms of inflammatory bowel disease (IBD).</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">Vedolizumab</a> is a gut selective anti-integrin agent that is not generally associated with systemic immunosuppression that is seen with anti-TNF agents. Pretreatment screening and adverse effects associated with vedolizumab are discussed separately. (See  <a class="medical medical_review" href="/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults", section on 'Anti-integrin antibodies'</a>.)</p><p></p><p>Most patients who respond to the induction dosing regimen of a biologic agent do not require long-term biologic therapy. In addition, while most guidelines suggest a glucocorticoid taper over four to six weeks, one contributor shortens the glucocorticoid taper to three to four weeks to decrease the risk of adverse effects related to concurrent glucocorticoid use and biologic therapy (eg, infection) [<a href="#rid27">27,45</a>].</p><p>Observational studies suggest that <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> were similarly beneficial for patients with ICI colitis [<a href="#rid46">46-48</a>]. In a study including 184 patients with ICI colitis who received glucocorticoid therapy followed by a biologic agent, rates of clinical remission were not significantly different for patients treated with vedolizumab compared with infliximab (89 versus 88 percent) [<a href="#rid46">46</a>]. Although vedolizumab was associated with shorter duration of glucocorticoid therapy compared with infliximab (35 versus 50 days), the time to achieve clinical response was longer with vedolizumab (17.5 versus 13 days).</p><p class="headingAnchor" id="H3790377599"><span class="h3">Nonresponders to initial biologic agent</span><span class="headingEndMark"> — </span>For patients with ICI colitis who do not respond to glucocorticoids plus the initial biologic agent (ie <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a>), we typically switch to a biologic agent from a different class (ie, from infliximab to vedolizumab or vice versa) [<a href="#rid48">48</a>].</p><p>For patients who do not respond to first- or second-line drug therapy, the efficacy and safety of other agents has not been well established [<a href="#rid32">32</a>]. However, limited data from case reports suggest that subsequent options may include <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> [<a href="#rid49">49</a>], <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> [<a href="#rid50">50,51</a>], or fecal microbiota transplantation [<a href="#rid22">22,52</a>].</p><p class="headingAnchor" id="H3868929575"><span class="h3">Resuming immune checkpoint inhibitors</span><span class="headingEndMark"> — </span>For patients with grade 2 or 3 ICI colitis who achieved symptomatic remission, the decision to reintroduce ICI therapy and selection of ICI agent is individualized and requires a multidisciplinary approach with input from specialists in oncology and gastroenterology.</p><p>For patients with grade 4 colitis, we recommend permanently discontinuing ICI therapy in most cases.</p><p>The approach to retreatment for patients with history of ICI toxicity is discussed separately. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Retreatment after prior toxicity'</a>.)</p><p>For patients who resume ICI therapy, the overall risk of recurrent ICI diarrhea and colitis is approximately 34 percent, including grade ≥3 diarrhea (5 percent), and grade ≥2 colitis (20 percent) [<a href="#rid53">53</a>]. Risk factors associated with recurrence include the use of an anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitor as the resumed agent and history of severe colitis that required immunosuppressive therapy to achieve remission.</p><p>In contrast, limited data suggest that using a biologic agent (eg, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a>) while resuming ICI therapy was associated with a lower risk of recurrent ICI colitis [<a href="#rid54">54,55</a>]. This approach remains investigational, and we await further studies prior to using it routinely in clinical practice.</p><p>If ICI colitis occurs with ICI rechallenge, the management is similar to treatment of the index episode.</p><p class="headingAnchor" id="H1088879000"><span class="h2">Monitoring patients with symptomatic remission</span><span class="headingEndMark"> — </span>For most patients who achieved symptomatic improvement (ie, grade 1 symptoms or less) with pharmacologic therapy and for whom ICI therapy will be resumed, we typically repeat endoscopic evaluation to assess for mucosal healing:</p><p class="headingAnchor" id="H1798484699"><span class="h3">Selecting a procedure</span><span class="headingEndMark"> — </span>The choice of procedure is based on the prior sites of inflammation. For example, patients who had left-sided colitis on initial lower endoscopy can be monitored with flexible sigmoidoscopy. Patients with isolated right-sided colitis or ileitis are monitored with ileocolonoscopy. Patients with isolated small bowel disease are monitored with esophagogastroduodenoscopy (EGD) and small bowel biopsies or with ileocolonoscopy with ileal biopsies, depending on the initial disease distribution.</p><p class="headingAnchor" id="H2673444104"><span class="h3">Procedure timing</span><span class="headingEndMark"> — </span>The timing of follow-up endoscopic evaluation is based on the treatment used. For those treated with glucocorticoids alone, we repeat endoscopic evaluation approximately two to four weeks after patients have discontinued glucocorticoid therapy. For those treated with biologic therapy, we repeat endoscopic evaluation after three doses of biologic therapy, or approximately eight weeks.</p><p class="headingAnchor" id="H416523982"><span class="h3">Postprocedure follow-up</span><span class="headingEndMark"> — </span>The approach to postprocedure management is determined by endoscopic findings and the therapy used to achieve symptomatic improvement:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endoscopic remission</strong> – Most patients with complete endoscopic remission (ie, no ulcers, no active inflammation) who were previously on biologic agents do not require maintenance therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Active mucosal disease</strong> – For patients with active mucosal disease but who have sustained symptomatic remission after a course of glucocorticoids alone, we monitor and retreat only if symptoms recur.</p><p></p><p class="bulletIndent1">For those with active mucosal disease who required biologic therapy to achieve symptomatic remission, we typically continue the biologic agent as maintenance therapy every four to eight weeks (with shorter intervals [ie, every four weeks] for those who develop recurrent symptoms or are planning to resume ICI therapy), and we repeat endoscopic evaluation after one to two maintenance doses.</p><p></p><p class="headingAnchor" id="H2760477392"><span class="h3">Alternatives to endoscopic evaluation</span><span class="headingEndMark"> — </span>For patients who cannot tolerate or do not want to undergo surveillance lower endoscopy, a stool inflammatory marker such as fecal calprotectin is a noninvasive alternative [<a href="#rid24">24,26</a>], although clinical practice varies for this approach. Stool inflammatory markers are obtained at initial diagnosis and every two to three months during immunosuppressive therapy for ICI colitis. If the calprotectin value is ≤116 microg/g, we typically taper glucocorticoids and discontinue biologic therapy if it had been initiated. Limited data suggest that stool inflammatory markers correlate with endoscopic disease activity. In one study, the specificity of a calprotectin value ≤116 microg/g to predict endoscopic remission was 94 percent [<a href="#rid26">26</a>]. </p><p>The goal of endoscopic monitoring is to target endoscopic remission, based on mucosal healing rather than on symptoms alone. Observational studies suggest that achieving endoscopic and histologic remission with pharmacologic therapy (ie, glucocorticoids and ≥3 doses of a biologic agent) was associated with lower risk of disease recurrence [<a href="#rid56">56</a>].</p><p>For the rare patient who continues biologic therapy as maintenance, additional monitoring is performed to screen for complications related to immunosuppression. Laboratory monitoring for patients on <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> includes complete blood count, complete metabolic panel, and C-reactive protein (CRP) with each infusion, and checking hepatitis B virus (HBV) serologies and interferon-gamma release assay annually. Colonoscopy is performed after one year of therapy and then periodically, based on symptoms. </p><p class="headingAnchor" id="H3042314661"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>If left untreated or not recognized promptly, patients with ICI colitis can develop severe disease and serious complications [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic megacolon</strong> — Toxic megacolon is a potentially lethal complication of ICI colitis, that is characterized by nonobstructive colonic dilatation plus systemic toxicity. The diagnosis and management of toxic megacolon is discussed separately. (See  <a class="medical medical_review" href="/d/html/1381.html" rel="external">"Toxic megacolon"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colonic perforation</strong> — Patients with ICI colitis who develop colonic perforation require colectomy, although this complication is rare. </p><p></p><p class="headingAnchor" id="H3946936386"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H106864183"><span class="h2">ICI-mediated microscopic colitis</span><span class="headingEndMark"> — </span>Some patients with ICI colitis have histologic features that resemble lymphocytic or collagenous colitis, and this condition is referred to as ICI-mediated microscopic colitis [<a href="#rid34">34-36</a>]. Patients with ICI-mediated microscopic colitis can present with a wide range and severity of clinical symptoms. Endoscopic examination may demonstrate visible mucosal inflammation which is not seen in patients with non-ICI microscopic colitis [<a href="#rid34">34-36</a>]. (See  <a class="medical medical_review" href="/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management", section on 'Diagnostic approach'</a>.)</p><p>Initial pharmacologic management typically includes an oral glucocorticoid (ie, oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> or <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>). For patients who are discontinuing ICI therapy, we treat with budesonide 9 mg daily for six weeks, followed by a three-week taper. For patients who remain on ICI therapy, we continue budesonide 9 mg daily indefinitely  (<a class="graphic graphic_table graphicRef116034" href="/d/graphic/116034.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management", section on 'Initial approach'</a>.)</p><p class="headingAnchor" id="H241921196"><span class="h2">Pre-existing chronic colitis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with inflammatory bowel disease</strong> – A history of inflammatory bowel disease (IBD) is not an absolute contraindication to treatment with ICIs. Patients with IBD still gain therapeutic benefit from ICI therapy, as data demonstrate cancer-specific survival in this population is similar to that reported in clinical trials of ICIs in the general population [<a href="#rid57">57,58</a>]. However, such patients are at increased risk for GI irAEs or flare of IBD. Therefore, collaborative input from both oncology and gastroenterology is necessary. Further details on the use of ICIs and the risk of irAEs in patients with autoimmune disease are discussed separately. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Pre-existing autoimmune disease'</a>.)</p><p></p><p class="bulletIndent1">Patients with pre-existing autoimmune diseases have previously been excluded from clinical trials evaluating ICI therapy. Therefore, management recommendations and colitis outcomes among patients with IBD are mostly based on observational studies [<a href="#rid57">57,59</a>]. As an example, one multicenter retrospective study evaluated the use of ICI therapy in 102 patients with IBD (approximately one-half with a diagnosis of ulcerative colitis and the other half with Crohn disease) [<a href="#rid58">58</a>]. Approximately 43 percent of patients were not on IBD-directed therapy at the time of ICI initiation. Most patients had either melanoma or lung cancer and received programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) inhibitors. In this study, the rate of GI irAEs was 41 percent, with 21 percent having severe symptoms. This rate is considerably higher than that noted in other control cohorts without IBD (approximately 11 percent) [<a href="#rid58">58</a>] or in clinical trials of PD-1/PD-L1 inhibitors. </p><p></p><p class="bulletIndent1">Patients with cancer and IBD who are interested in the use of ICIs may also enroll in clinical trials, where available. A multicenter clinical trial is actively evaluating the use of ICIs in cancer patients with IBD (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03816345&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPOYjkhwm9iS3H6W%2FMWSvIuFvhEVyaJblcACLZ8Zu7YA9w%3D%3D&amp;TOPIC_ID=138429" target="_blank">NCT03816345</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with microscopic colitis</strong> – In addition to IBD, other autoimmune GI diseases have also been recognized. In one retrospective cohort study, among four patients with pre-existing microscopic colitis who were treated with ICI therapy, three patients developed a colitis flare that required holding cancer treatment and the use of immunosuppressants [<a href="#rid57">57</a>]. </p><p></p><p class="headingAnchor" id="H1896002813"><span class="h1">IS THERE A ROLE FOR PROPHYLAXIS?</span><span class="headingEndMark"> — </span>We do not use pharmacologic prophylaxis (eg, glucocorticoids or biologic agents) to prevent ICI-related colitis, because data to support this approach is limited [<a href="#rid60">60,61</a>]. Further prospective studies are necessary. </p><p>As an example, in a trial of 115 patients with advanced melanoma treated with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, the use of <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> prophylaxis did not result in lower rates of grade ≥2 diarrhea compared with placebo (33 versus 35 percent) [<a href="#rid60">60</a>]. These results are likely generalizable to patients with other types of cancer as well as with use of other ICIs routinely in clinical practice. </p><p class="headingAnchor" id="H2283371699"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/134785.html" rel="external">"Society guideline links: Management of toxicities due to checkpoint inhibitor immunotherapy"</a>.)</p><p class="headingAnchor" id="H3213373865"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Immune checkpoint inhibitor (ICI) colitis is the most frequently reported gastrointestinal (GI) immune-related adverse event. Patients with ICI colitis usually present with diarrhea of variable clinical frequency. Symptoms usually develop within a few weeks to a few months after starting therapy. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with more severe disease, diarrhea may be associated cramping abdominal pain, urgency, and rectal bleeding.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Less typical symptoms such as fever, abdominal distension, and/or severe abdominal pain should raise suspicion for severe disease and/or possible colonic perforation or toxic megacolon. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of ICI colitis should be suspected in patients who are receiving ICI therapy and who develop diarrhea with or without bleeding or abdominal pain. The diagnosis is established clinically by assessing symptoms according to Common Terminology Criteria for Adverse Events (CTCAE  (<a class="graphic graphic_table graphicRef65649 graphicRef138439" href="/d/graphic/65649.html" rel="external">table 1A-B</a>)) and excluding other causes (eg, infection). The diagnosis may be further confirmed with endoscopic evaluation with biopsies. (See <a class="local">'Diagnostic evaluation'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory testing</strong> – For all patients in whom ICI colitis is suspected, laboratory studies including blood tests and stool studies are obtained. (See <a class="local">'Laboratory studies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lower endoscopy with biopsies</strong> – For patients with grade 2 to 4 symptoms and/or an elevated stool inflammatory marker, we typically perform a lower endoscopy (eg, flexible sigmoidoscopy) with biopsies. While flexible sigmoidoscopy is the initial test of choice, some contributors start with an ileocolonoscopy to also assess for right-sided colitis or ileitis. Patients with persistent symptoms but with a normal flexible sigmoidoscopy or colonoscopy can subsequently be evaluated with upper esophagogastroduodenoscopy (EGD). (See <a class="local">'Endoscopic evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imaging studies</strong> – For patients with a suspected complication (eg, those with fever, severe abdominal pain, abdominal distension, and/or bleeding), we perform cross sectional imaging (CT of the abdomen and pelvis) prior to endoscopic evaluation to exclude complications of ICI colitis (eg, bowel perforation or toxic megacolon) as well as potential cancer progression. (See <a class="local">'Imaging studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The initial management of ICI-mediated colitis is based on severity of disease using the Common Terminology Criteria for Adverse Events (CTCAE  (<a class="graphic graphic_table graphicRef65649 graphicRef138439" href="/d/graphic/65649.html" rel="external">table 1A-B</a>)). For patients treated with ICI therapy alone and with different grading for diarrhea and colitis, we use the higher grade to guide treatment decisions. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild disease (grade 1)</strong> – Patients with mild (grade 1) symptoms are managed with supportive care and may typically continue ICI therapy. We do not initiate systemic glucocorticoids. (See <a class="local">'Mild disease (grade 1)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate to severe disease</strong> <strong>(grade 2 to 4)</strong> – Patients with moderate to severe (grade 2 to 4) symptoms are managed as follows (see <a class="local">'Moderate to severe disease (grade 2 to 4)'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We hold ICI therapy temporarily for grades 2 to 3 symptoms and typically discontinue it permanently for grade 4 symptoms.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We confirm that GI infection has been excluded based on stool studies prior to initiating systemic glucocorticoids. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with grade 2 to 3 diarrhea without systemic symptoms (eg, fever, hypotension) and who are tolerating oral intake, we suggest initiating glucocorticoid therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We begin oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> at a dose of 1 mg/kg by mouth daily) or an equivalent agent. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients who do not have clinical improvement on oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> after three days; those with grade 4 symptoms; and those with grade 2 to 3 symptoms who have systemic symptoms and/or are not tolerating oral intake are treated with intravenous glucocorticoid therapy and typically require hospitalization. We treat with <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 1 to 2 mg/kg daily (in two divided doses with a maximum total daily dose of 120 mg  (<a class="graphic graphic_algorithm graphicRef138880" href="/d/graphic/138880.html" rel="external">algorithm 1</a>)).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subsequent management </strong>– For patients who do not have symptomatic improvement within three days of initiating glucocorticoids or for those with high-risk endoscopic features (eg, colonic ulcers with Mayo Endoscopic score 3 or greater (<a class="calc calc_professional" href="/d/html/15644.html" rel="external">calculator 1</a>)), we suggest the addition of a biologic agent (either <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a>) to glucocorticoid therapy rather than glucocorticoids alone or other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The choice between infliximab and vedolizumab is based on clinician preference, patient comorbidities, and the type of cancer, as efficacy is comparable between the two agents. (See <a class="local">'Subsequent management (biologic agents)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for remission</strong> – For most patients who achieved symptomatic improvement (ie, grade 1 symptoms or less) with pharmacologic therapy and for whom ICI therapy will be resumed, we repeat endoscopic evaluation to assess for mucosal healing. (See <a class="local">'Monitoring patients with symptomatic remission'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol 2020; 115:202.</a></li><li class="breakAll">Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. United States Department of Health and Human Services. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf (Accessed on January 22, 2021).</li><li><a class="nounderline abstract_t">Som A, Mandaliya R, Alsaadi D, et al. Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Clin Cases 2019; 7:405.</a></li><li><a class="nounderline abstract_t">Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24:2283.</a></li><li><a class="nounderline abstract_t">Pauken KE, Dougan M, Rose NR, et al. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends Immunol 2019; 40:511.</a></li><li><a class="nounderline abstract_t">Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol 2018; 4:1721.</a></li><li><a class="nounderline abstract_t">Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521.</a></li><li><a class="nounderline abstract_t">Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691.</a></li><li><a class="nounderline abstract_t">Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155.</a></li><li><a class="nounderline abstract_t">Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 2018; 6:37.</a></li><li><a class="nounderline abstract_t">Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 2017; 28:1368.</a></li><li><a class="nounderline abstract_t">Grover S, Dougan M, Tyan K, et al. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer 2020; 126:3758.</a></li><li><a class="nounderline abstract_t">Dougan M, Luoma AM, Dougan SK, Wucherpfennig KW. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 2021; 184:1575.</a></li><li><a class="nounderline abstract_t">Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 2016; 375:1749.</a></li><li><a class="nounderline abstract_t">Cohen JV, Dougan M, Zubiri L, et al. Liver biopsy findings in patients on immune checkpoint inhibitors. Mod Pathol 2021; 34:426.</a></li><li><a class="nounderline abstract_t">Marthey L, Mateus C, Mussini C, et al. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis 2016; 10:395.</a></li><li><a class="nounderline abstract_t">Sasson SC, Slevin SM, Cheung VTF, et al. Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis. Gastroenterology 2021; 161:1229.</a></li><li><a class="nounderline abstract_t">Luoma AM, Suo S, Williams HL, et al. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell 2020; 182:655.</a></li><li><a class="nounderline abstract_t">Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov 2017; 7:188.</a></li><li><a class="nounderline abstract_t">Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med 2016; 375:819.</a></li><li><a class="nounderline abstract_t">Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 2016; 7:10391.</a></li><li><a class="nounderline abstract_t">Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 2018; 24:1804.</a></li><li><a class="nounderline abstract_t">Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management. Am Soc Clin Oncol Educ Book 2018; 38:13.</a></li><li><a class="nounderline abstract_t">Abu-Sbeih H, Ali FS, Luo W, et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2018; 6:95.</a></li><li><a class="nounderline abstract_t">Vuillamy C, Arnault JP, Fumery M, et al. Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature. Melanoma Res 2023; 33:192.</a></li><li><a class="nounderline abstract_t">Zou F, Wang X, Glitza Oliva IC, et al. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J Immunother Cancer 2021; 9.</a></li><li><a class="nounderline abstract_t">Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflamm Bowel Dis 2018; 24:1695.</a></li><li><a class="nounderline abstract_t">Pisuchpen N, Durbin SM, Mooradian MJ, et al. Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. Eur Radiol 2021; 31:8868.</a></li><li><a class="nounderline abstract_t">Durbin SM, Mooradian MJ, Fintelmann FJ, et al. Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. J Immunother Cancer 2020; 8.</a></li><li><a class="nounderline abstract_t">Wright AP, Piper MS, Bishu S, Stidham RW. Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther 2019; 49:1474.</a></li><li><a class="nounderline abstract_t">Herlihy JD, Beasley S, Simmelink A, et al. Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis. South Med J 2019; 112:154.</a></li><li><a class="nounderline abstract_t">Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology 2021; 160:1384.</a></li><li><a class="nounderline abstract_t">Mooradian MJ, Wang DY, Coromilas A, et al. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer 2020; 8.</a></li><li><a class="nounderline abstract_t">Choi K, Abu-Sbeih H, Samdani R, et al. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity? Inflamm Bowel Dis 2019; 25:385.</a></li><li><a class="nounderline abstract_t">Hughes MS, Molina GE, Chen ST, et al. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer 2019; 7:292.</a></li><li><a class="nounderline abstract_t">Janela-Lapert R, Bouteiller J, Deschamps-Huvier A, et al. Anti-PD-1 induced collagenous colitis in metastatic melanoma: a rare severe adverse event. Melanoma Res 2020; 30:603.</a></li><li><a class="nounderline abstract_t">Bello E, Cohen JV, Mino-Kenudson M, Dougan M. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. J Immunother Cancer 2019; 7:41.</a></li><li><a class="nounderline abstract_t">Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021; 39:4073.</a></li><li><a class="nounderline abstract_t">Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; 5:95.</a></li><li><a class="nounderline abstract_t">Thompson JA, Schneider BJ, Brahmer J, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw 2020; 18:230.</a></li><li><a class="nounderline abstract_t">Rastogi P, Sultan M, Charabaty AJ, et al. Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital. World J Gastroenterol 2015; 21:4373.</a></li><li><a class="nounderline abstract_t">Gonzalez RS, Salaria SN, Bohannon CD, et al. PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'. Histopathology 2017; 70:558.</a></li><li><a class="nounderline abstract_t">Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 2018; 3:e000278.</a></li><li><a class="nounderline abstract_t">Zou F, Shah AY, Glitza IC, et al. Comparative study of vedolizumab and infliximab treatment in patients with immune-mediated diarrhea and colitis. Am J Gastroenterol 2020; 115:s68.</a></li><li><a class="nounderline abstract_t">Abu-Sbeih H, Tang T, Shaukat Ali F, et al. The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients’ outcomes. Journal of Immunotherapy and Precision Oncology 2018; 1:7.</a></li><li><a class="nounderline abstract_t">Zou F, Faleck D, Thomas A, et al. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 2021; 9.</a></li><li><a class="nounderline abstract_t">Johnson DH, Zobniw CM, Trinh VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 2018; 6:103.</a></li><li><a class="nounderline abstract_t">Abu-Sbeih H, Ali FS, Alsaadi D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer 2018; 6:142.</a></li><li><a class="nounderline abstract_t">Thomas AS, Ma W, Wang Y. Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors. N Engl J Med 2021; 384:581.</a></li><li><a class="nounderline abstract_t">Esfahani K, Hudson M, Batist G. Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. N Engl J Med 2020; 382:2374.</a></li><li><a class="nounderline abstract_t">Bishu S, Melia J, Sharfman W, et al. Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis. Gastroenterology 2021; 160:932.</a></li><li><a class="nounderline abstract_t">Abu-Sbeih H, Ali FS, Wang Y. Clinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients. Curr Gastroenterol Rep 2019; 21:8.</a></li><li><a class="nounderline abstract_t">Abu-Sbeih H, Ali FS, Naqash AR, et al. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol 2019; 37:2738.</a></li><li><a class="nounderline abstract_t">Badran YR, Cohen JV, Brastianos PK, et al. Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer 2019; 7:226.</a></li><li><a class="nounderline abstract_t">Abu-Sbeih H, Tang T, Faleck DM, et al. Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study. J Clin Oncol 2021; 39:suppl_2643.</a></li><li><a class="nounderline abstract_t">Abu-Sbeih H, Ali FS, Wang X, et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2019; 7:93.</a></li><li><a class="nounderline abstract_t">Grover S, Ruan AB, Srivoleti P, et al. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. JCO Oncol Pract 2020; 16:e933.</a></li><li><a class="nounderline abstract_t">Abu-Sbeih H, Faleck DM, Ricciuti B, et al. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. J Clin Oncol 2020; 38:576.</a></li><li><a class="nounderline abstract_t">Gong Z, Wang Y. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. JCO Oncol Pract 2020; 16:453.</a></li><li><a class="nounderline abstract_t">Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15:5591.</a></li><li><a class="nounderline abstract_t">Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10:11.</a></li></ol></div><div id="topicVersionRevision">Topic 138429 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31922959" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Checkpoint Inhibitor-Induced Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31922959" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Checkpoint Inhibitor-Induced Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30842952" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Immune checkpoint inhibitor-induced colitis: A comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16710025" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31053497" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30242316" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25891173" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pembrolizumab versus Ipilimumab in Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22614989" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Management of immune-related adverse events and kinetics of response with ipilimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20004617" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29747688" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28368458" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32567084" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33675691" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Understanding and treating the inflammatory adverse events of cancer immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27806233" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Fulminant Myocarditis with Combination Immune Checkpoint Blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32884128" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Liver biopsy findings in patients on immune checkpoint inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26783344" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34147519" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32603654" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27903500" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27433843" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26837003" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30420754" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30231401" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30253811" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36995276" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33436487" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29718308" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34081152" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33033184" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31035308" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30830228" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33080231" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32414860" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30169584" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31699151" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Budesonide treatment for microscopic colitis from immune checkpoint inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32404733" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Anti-PD-1 induced collagenous colitis in metastatic melanoma: a rare severe adverse event.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30744698" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34724392" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29162153" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32135517" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25892889" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28000302" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29387476" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Comparative study of vedolizumab and infliximab treatment in patients with immune-mediated diarrhea and colitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients’outcomes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34789551" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30305177" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30518410" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33567198" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32521140" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33096100" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30815766" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31163011" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31439050" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Concurrent therapy with immune checkpoint inhibitors and TNFαblockade in patients with gastrointestinal immune-related adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30940209" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32401685" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31800340" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32584703" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19671877" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21090563" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
